Based on the foregoing, the hypertrophic heart displaying a substrate switch toward increased glucose utilization might benefit from drugs that specifically inhibit PKD1, especially in advanced stages of cardiac hypertrophy (pathological remodeling). Here, PKD1 is linked to cardiac hypertrophy.